Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Maat Pharma S.a. Stock

Price
Target price
€7.12

€7.12

-0.280%
-0.02
-0.280%
€10.00
 
25.07.24 / Frankfurt WKN: A3C7A5 / Name: Maat Pharma S.a. / Stock / ? /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Maat Pharma S.a. in the next few years
Wizard

Financial data and news for Maat Pharma S.a.

sharewise wants to provide you with the best news and tools for Maat Pharma S.a., so we directly link to the best financial data sources.

Financials

News

Broker

 

News

MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT: https://mms.businesswire.com/media/20211211005036/en/729326/5/Nov_2018_new_version_MaaT_Pharma_logo.jpg
MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to

BusinessWire_EN 
0 02.07.24
MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16: https://mms.businesswire.com/media/20211211005036/en/729326/5/Nov_2018_new_version_MaaT_Pharma_logo.jpg
MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to

BusinessWire_EN 
0 25.06.24
MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer: https://mms.businesswire.com/media/20211211005036/en/729326/5/Nov_2018_new_version_MaaT_Pharma_logo.jpg
MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to

BusinessWire_EN 
0 24.06.24
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024: https://mms.businesswire.com/media/20211211005036/en/729326/5/Nov_2018_new_version_MaaT_Pharma_logo.jpg
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to

BusinessWire_EN 
0 07.05.24
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event: https://mms.businesswire.com/media/20211211005036/en/729326/5/Nov_2018_new_version_MaaT_Pharma_logo.jpg
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to

BusinessWire_EN 
0 15.04.24
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies: https://mms.businesswire.com/media/20211211005036/en/729326/5/Nov_2018_new_version_MaaT_Pharma_logo.jpg
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to

BusinessWire_EN 
0 08.04.24
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale: https://mms.businesswire.com/media/20211211005036/en/729326/5/Nov_2018_new_version_MaaT_Pharma_logo.jpg
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to

BusinessWire_EN 
0 05.04.24
MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview: https://mms.businesswire.com/media/20211211005036/en/729326/5/Nov_2018_new_version_MaaT_Pharma_logo.jpg
MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to

BusinessWire_EN 
0 28.03.24
MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer: https://mms.businesswire.com/media/20211211005036/en/729326/5/Nov_2018_new_version_MaaT_Pharma_logo.jpg
MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to

BusinessWire_EN 
0 21.03.24
MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To improve Patients’ Responses to Immunotherapies: https://mms.businesswire.com/media/20211211005036/en/729326/5/Nov_2018_new_version_MaaT_Pharma_logo.jpg
MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To improve Patients’ Responses to Immunotherapies


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to

BusinessWire_EN 
0 19.03.24
MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference: https://mms.businesswire.com/media/20211211005036/en/729326/5/Nov_2018_new_version_MaaT_Pharma_logo.jpg
MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to

BusinessWire_EN 
0 12.03.24
MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma: https://mms.businesswire.com/media/20211211005036/en/729326/5/Nov_2018_new_version_MaaT_Pharma_logo.jpg
MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to

BusinessWire_EN 
0 05.03.24
MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS): https://mms.businesswire.com/media/20211211005036/en/729326/5/Nov_2018_new_version_MaaT_Pharma_logo.jpg
MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to

BusinessWire_EN 
0 29.02.24